Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
3689-50-7
Molecular formula
C18H22N2O2S
Molecular weight
330.4 g/mol
Drug class
First-generation phenothiazine H1 antihistaminesedating antiallergic and antitussive agent
Mechanism of action
Antagonises histamine H1 receptors and has antimuscarinic properties. Central H1 antagonism contributes to sedation and cough suppression; it is commonly used as a component of cough/cold combination products.
Indications / reported uses
Symptomatic treatment of cough, particularly dry or irritative cough, in countries where oxomemazine-containing products are authorised.
Relief of allergic symptoms with antihistamine activity; formulation and combination product determine specific indications.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Oxomemazine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Oxomemazine Permitted Daily Exposure (PDE) report (the Oxomemazine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Oxomemazine Occupational Exposure Limit (OEL) report (the Oxomemazine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.